BioPorto in court settlement and Abbott-alliance
BioPorto can now close the chapter on a lengthy court case, just as the Danish diagnostics company has penned a deal with arch rival Abbott.
by Leonora Beck
The NGAL test for acute kidney injury has been the focus of a lot of attention in recent years, not least in court rooms in relation to patent rights for the product. But BioPorto has now settled a patent trial at the Danish supreme court with Swedish company Phadia. It effectively means BioPorto will gain a license to Phadia’s global patents relating to the NGAL test.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
BioPorto: Focus on sales pays off
For abonnenter
BioPorto: Postponement is very positive
For abonnenter
Bioporto secures patent in China
For abonnenter
